Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05839912 · ClinicalTrials.gov registry record · NA
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
A NA study of Melanoma, sponsored by Craig L Slingluff, Jr.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 7
- Study locations
NCT05839912: Recruiting NA study of Melanoma, sponsored by Craig L Slingluff, Jr.
NCT05839912 is a NA study of Melanoma that is actively recruiting participants, run by Craig L Slingluff, Jr. The registered enrollment target is 66 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05839912, a NA study of Melanoma, is actively recruiting participants, sponsored by Craig L Slingluff, Jr.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and how much the surgery impacts quality of life. In order to be eligible for this study, participants must have been diagnosed with metastatic melanoma and have one detected cancerous lymph node by imaging (CT/PET scan) or clinical examination, and are a candidate for lymph node excision.
Primary Outcome
Number of participants with recurrence of melanoma within the node basin without concurrent or preceding distant metastatic recurrence
Conditions Studied
Interventions
- PROCEDURE Excision of clinically detected lymph node metastasis before any systemic therapy
- PROCEDURE Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Study Locations (7)
Georgia
- Emory University - Atlanta
Maryland
- University of Maryland - Baltimore
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Health System - Durham
Pennsylvania
- University of Pennsylvania - Philadelphia
Virginia
- Cancer Center at the University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2028-09-01 |
| Phase | NA |
What NCT05839912 shows while recruiting
NCT05839912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Excision of clinically detected lymph node metastasis before any systemic therapy is the first listed.
NCT05839912 lists 7 locations in 7 states (Georgia, Maryland, Michigan).
Frequently Asked Questions
What is clinical trial NCT05839912 about?
NCT05839912 is a clinical study titled "Excision of Lymph Node Trial (EXCILYNT) (Mel69)". The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and h...
What is the current status of trial NCT05839912?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2023-09-06. Estimated completion is 2028-09-01.
What conditions does trial NCT05839912 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT05839912?
The interventions under investigation include: Excision of clinically detected lymph node metastasis before any systemic therapy (PROCEDURE), Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05839912?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05839912 being conducted?
This trial has 7 study locations across Georgia, Maryland, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05839912's enrollment target sits among peer trials
66 144th of 266 higher than 123 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI